YI 111, Inc. Annual reports only
Retail-Drug Stores and Proprietary Stores · Nasdaq · SEC CIK 1738906 · Reporting currency CNY · Fiscal year ends 12/31
Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY51.5%
TTM net income YoY-27.0%
TTM EPS YoY-45.8%
Revenue 3-yr CAGR90.9%
Net income 3-yr CAGR—
Margins
Gross margin5.0%
Operating margin-5.2%
Net margin-4.8%
FCF margin-6.0%
EBITDA margin-4.9%
Returns
ROE-644.5%
ROA-19.2%
ROIC (approx.)—
Asset turnover4.03x
Leverage & solvency
Liabilities / assets73.0%
Debt / equity—
Current ratio1.32x
Interest coverage-117.01x
Cash quality & payout
Operating cash flow / net income1.16x
Accruals ratio3.1%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CNY | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 12.56B | 14.40B |
| Cost of revenue | 11.83B | 13.57B |
| Gross profit | 723.41M | 829.23M |
| SG&A expense | 69.46M | 70.91M |
| Operating income | -2.38M | 2.11M |
| Interest expense | 35.57M | 28.33M |
| Pretax income | -22.50M | -20.68M |
| Income tax | 13,000 | 96,000 |
| Net income | -18.42M | -12.38M |
| EBITDA | 9.46M | 19.08M |
| EPS (basic) | -0.38 | -0.38 |
| EPS (diluted) | -0.38 | -0.38 |
| Weighted avg. shares (diluted) | 174.03M | 171.84M |
| Balance sheet | ||
| Cash & equivalents | 510.97M | 462.29M |
| Short-term investments | 50.03M | — |
| Receivables | 259.69M | 413.10M |
| Inventory | 998.47M | 1.39B |
| Current assets | 2.12B | 2.65B |
| PP&E, net | 21.11M | 32.90M |
| Intangibles | 868,000 | 1.44M |
| Total assets | 2.20B | 2.79B |
| Current liabilities | 1.95B | 2.34B |
| Short-term debt | 187.63M | 160.98M |
| Total liabilities | 1.99B | 2.41B |
| Shareholders' equity | -702.23M | -642.64M |
| Cash flow statement | ||
| Operating cash flow | 119.14M | 263.02M |
| Capital expenditure | 4.45M | 15.20M |
| Free cash flow | 114.69M | 247.82M |
| Investing cash flow | -53.72M | 37.38M |
| Financing cash flow | -21.19M | -406.24M |
| Depreciation & amortization | 11.84M | 16.97M |
| Stock-based compensation | 10.05M | 20.15M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, CNY, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.